Review anchor
Peroxisome proliferator-activated receptor delta
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Peroxisome proliferator-activated receptor delta
CHEMBL3979
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Peroxisome proliferator-activated receptor delta as ChEMBL target CHEMBL3979, mapped to UniProt Q03181. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3979
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q03181
Peroxisome proliferator-activated receptor delta
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Peroxisome proliferator-activated receptor delta matters
Peroxisome proliferator-activated receptor delta is reviewed as Peroxisome proliferator-activated receptor delta (UniProt Q03181); Peroxisome proliferator-activated receptor delta shows approved-linked disease relevance led by biliary liver cirrhosis. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 5 approved drugs, 3861 compounds, and 677 assays, with lead potency reaching pChEMBL 11.0.
Protein context
Peroxisome proliferator-activated receptor delta
Peroxisome proliferator-activated receptor delta Sequence length is 441 aa.
Review this target as Peroxisome proliferator-activated receptor delta, mapped to UniProt Q03181. Sequence length is 441 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q03181
Protein
Disease context
biliary liver cirrhosis
Peroxisome proliferator-activated receptor delta shows approved-linked disease relevance led by biliary liver cirrhosis. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include SELADELPAR LYSINE.
Start review with biliary liver cirrhosis because it currently carries approved-linked support. Linked drugs include SELADELPAR LYSINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 5 approved drugs, 3861 compounds, and 677 assays for this target. The dominant activity type is EC50. CHEMBL387921 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL387921 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
5 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Peroxisome proliferator-activated receptor delta matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q03181, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why biliary liver cirrhosis is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
3861
Total Compounds
677
Total Assays
5
Approved Drugs
IC50: 869.0, KI: 138.0, EC50: 2577.0, KD: 24.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL387921
|
11.0 | Ki | — |
|
|
No preferred name
CHEMBL390005
|
10.5 | EC50 | — |
|
|
No preferred name
CHEMBL38943
|
10.3 | Ki | Clinical |
|
|
No preferred name
CHEMBL230063
|
10.2 | EC50 | — |
|
|
No preferred name
CHEMBL5931937
|
10.0 | EC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
SELADELPAR
CHEMBL230158
|
2024 |
|
|
ELAFIBRANOR
CHEMBL3707395
|
2024 |
Source Header